SEARCH RESULT

Total Matching Records found : 97

India's patent ruling on cancer may open door for cheaper HIV drugs

-Reuters India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say.  On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug...

More »

Natco gets India’s first compulsory licence-CH Unnikrishnan

In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...

More »

Anna to rest, calls off poll campaign

-The Telegraph   Anna Hazare will not campaign in the five election-bound states because of his poor health, aide Kiran Bedi said today. The Team Anna member said Hazare, 74, had been advised complete rest, and therefore he would not undertake the promised tour of Uttar Pradesh, Uttarakhand, Punjab, Goa and Manipur, which are going to the polls from January 28 to March 3. “Anna is not going to campaign in the states. We...

More »

Lethal mix R Ramachandran

It is the improper mode of application, violating the law and regulations, that is responsible for the apparent adverse toxic effects of endosulfan. FROM a scientific perspective, an extremely pertinent question in the endosulfan story is why adverse health effects similar to those seen in the villages of Kasaragod district in Kerala have not been reported from other parts of the country where the pesticide is used in much larger...

More »

Survey points to TB pill violation by GS Mudur

Nearly 60 per cent of tuberculosis medication dose strengths sold in India through prescriptions of private practitioners do not conform with standard TB treatment guidelines, a study has revealed. The findings corroborate suggestions made by some Indian doctors — several times over the past two decades — that a majority of private practitioners do not write correct prescriptions for treating TB. The government’s TB control programme provides free TB treatment to more...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close